
Mark Hyman | Written in his personal capacity
This year a 15-year-old boy has been admitted to hospital again and again as his own complement system destroyed his red blood cells. His haemoglobin fell to 5.7 g/dL. The intervals between emergency admissions shrank from 143 days to 23, and then to 13. His treating haematologist prescribed ravulizumab (Ultomiris), a complement inhibitor that stops the destruction. His Medical Scheme said it was not a Prescribed Minimum Benefit.
On 29 October 2026 the Appeals Committee of the Council for Medical Schemes disagreed. It overruled the CMS Registrar and directed KeyHealth Medical Scheme to fund ravulizumab (Ultomiris) in full, without an option upgrade, co-payment, deductible or use of his medical savings. I represented his father in that appeal. I write not to argue it again, but because the route this family had to travel says something every Medical Scheme, regulator and policymaker should hear.
What the law already says
Nobody disputed that paroxysmal nocturnal haemoglobinuria (PNH) is a PMB condition. It is listed under Diagnosis and Treatment Pair 113S. Once that is established, Regulation 8(1) of the General Regulations (GN R1262) leaves no room for negotiation:
“Subject to the provisions of this regulation, any benefit option that is offered by a medical scheme must pay in full, without co-payment or the use of deductibles, the diagnosis, treatment and care costs of the prescribed minimum benefit conditions.”
Section 29(1)(o) of the Medical Schemes Act 131 of 1998 requires every scheme’s rules to provide for “the scope and level of minimum benefits that are to be available to beneficiaries as may be prescribed”. Nowhere does the Act say that a minimum benefit is whatever the public sector happens to procure. That test comes from Explanatory Note 2 to Annexure A, which ties “medical management” to prevailing public hospital practice. The Committee confirmed what the hierarchy of law requires: a note cannot defeat the regulation it explains.
Regulation 15H(c) adds a safeguard that is too often forgotten. Managed care protocols must:
“provide for appropriate exceptions where a protocol has been ineffective or causes or would cause harm to a beneficiary, without penalty to that beneficiary”.
Transfusions and iron infusions had been both ineffective and harmful for this child. The Committee recorded that the threshold for an exception was decisively met.
Why it still took an appeal
KeyHealth refused funding outright on 28 May 2026. Only after MediCheck intervened did it offer a package: funding limited to 50%, a compulsory upgrade from the Equilibrium option to Platinum, settlement of savings deficits, a two-year membership lock-in, clawbacks, and reassessment of funding upon any hospital admission. In PNH, hospital admission is precisely the moment treatment matters most. The Committee found these conditions inconsistent with Regulation 8 and with Regulation 10(6), which protects medical savings from being used for PMB costs.
Nor was this a Scheme under financial strain. The Committee recorded an audited 2025 solvency ratio of 41.6%, against the 25% minimum in Regulation 29, and a net surplus of R249.1 million.
The law was clear and the money was there. What was missing was a framework that makes the answer obvious at the authorisation desk, before a child waits months for it. This case exposes three pressures on Annexure A.
- A benchmark that stands still. Annexure A has not been substantially reviewed since 2003. Ravulizumab was only registered by SAHPRA in May 2026. A floor that never moves sinks steadily below the standard of care.
- Rare disease falls through the floor. PNH affects one to two people per million. Public procurement seldom reaches conditions this rare, so a benchmark tied to it leaves these patients with a listed condition and no defined treatment.
- A condition without content. Annexure A names the condition but leaves the level of care open to dispute. Every case starts from first principles, and the Committee itself stressed that its ruling binds only this matter. The next family must prove it all again.
What should happen next
- The Minister of Health should prioritise, under section 67 of the Act, a revision of Annexure A that defines the level of care for each condition explicitly and keeps it current, rather than leaving it to be inferred from public-sector practice.
- The Council for Medical Schemes should accelerate its PMB definition guideline work and establish a transparent, dedicated pathway for rare and ultra-rare conditions, so that access does not depend on litigation.
- The Registrar should issue a circular reminding Medical Schemes that option upgrades, partial funding, lock-ins, clawbacks and hospitalisation-triggered withdrawal cannot be attached to PMB treatment, given the unconditional terms of Regulation 8(1).
- Medical Schemes should apply Regulation 15H(c) exceptions at the authorisation stage, where the Regulations place them, and not wait for an appeal to compel it.
The child at the centre
Section 28(2) of the Constitution provides that “a child’s best interests are of paramount importance in every matter concerning the child”, and section 9 of the Children’s Act 38 of 2005 makes that the standard in every matter concerning a child’s care and well-being. This boy’s interests prevailed because his family had the stamina to persist, a specialist willing to give evidence, and representation through two forums. The next family may have none of those. The Minister, the Council and the Registrar hold the instruments to ensure that the outcome no longer depends on them.
About the author
1. Mark Hyman is the Founder and CEO of MediCheck, a South African Medical Scheme member advocacy practice, and a Full Voting Member, Clinical Advisory Committee, Council for Medical Schemes.
2. He has more than four decades of experience across retail pharmacy, capitated primary care, managed care, electronic claims adjudication and member advocacy, and is the founder of Citizens for Integrity NPC.
3. He writes in his personal capacity. The views expressed are his own and not those of the Council for Medical Schemes or any of its committees.